Table 4 Patient Outcomes: lipid panel variations, patients who have reached their lipid goals and incidence rate of cardiovascular events and all-cause mortality

 Total cholesterol, mg/dL; initial

223.9 [222.7–225.1]

223.2 [222.4–224.0]

223.3 [222.8–223.8]

0.489

 Total cholesterol, mg/dL; final

189.4 [188.1–190.7]

192.8 [191.9–193.7]

192.0 [191.4–192.6]

< 0.001

 Difference (initial – final)

−34.5

−30.4

−31.3

< 0.001

 Triglycerides, mg/dL; initial

141.7 [140.2–143.2]

142.5 [141.6–143.4]

142.3 [141.7–142.9]

0.619

 Triglycerides, mg/dL: final

129.8 [128.5–131.1]

133.8 [133.1–134.5]

132.9 [132.4–133.4]

0.014

 Difference (initial – final)

−11.9

−8.7

−9.4

< 0.001

 High-density lipoprotein cholesterol, mg/dL; initial

50.1 [48.3–51.9]

50.2 [49.0–51.4]

50.2 [49.3–51.1]

0.993

 High-density lipoprotein cholesterol, mg/dL; final

55.7 [53.8–57.6]

54.3 [53.0–55.6]

54.5 [53.6–55.4]

< 0.001

 Difference (initial – final)

5.6

4.1

4.3

0.035

 Low-density lipoprotein cholesterol, mg/dL; initial

135.6 [133.7–137.5]

135.1 [133.6–136.6]

135.2 [134.3–136.1]

0.485

 Low-density lipoprotein cholesterol, mg/dL; final

118.6 [116.8–120.4]

121.5 [120.1–123.0]

120.8 [120.2–121.4]

< 0.001

 Difference (initial – final)

−17.0

−13.6

−14.4

< 0.001

 At the start of statin therapy

17.9 [16.5–19.3]

17.7 [16.9–18.4]

17.7 [17.1–18.4]

0.811

 At discontinuation

42.0 [40.2–43.7]

39.2 [38.3–40.2]

39.9 [39.0–40.7]

OR; 0.87 [0.80–0.95], p = 0.003

 Absolute variation

24.1

21.5

22.2

< 0.001

- Any cardiovascular event

31.48 [27.85–35.46]

39.56 [37.24–41.99]

37.63 [35.65–39.69]

< 0.001

­ CHD event

14.41 [11.98–17.18]

18.76 [17.17–20.45]

17.71 [16.36–19.14]

0.008

­ Stroke

17.08 [14.43–20.07]

20.81 [19.13–22.59]

19.91 [18.48–21.43]

0.033

- All-cause mortality

18.82 [16.03–21.95]

25.09 [23.25–27.04]

23.59 [22.03–25.23]

< 0.001